Clinicians have been aware of the increased prevalence of low testosterone levels in patients with type II diabetes for several years, but how these two conditions are associated is difficult to determine. Older age and obesity may be factors, as both are associated with type II diabetes and both decrease testosterone levels. Sex hormone-binding globulin (SHBG), the major serum carrier protein for testosterone, also may have an impact. SHBG levels fall with obesity and increase with aging. Some studies indicate lower SHBG levels in type II diabetes. Most of the differences in testosterone levels between diabetic and nondiabetic patients may be due to reduced SHBG, rather than reduced testosterone production. However, free testosterone levels fall with increasing age and obesity, rendering many type II diabetic patients testosterone deficient. Testosterone replacement may improve insulin sensitivity in hypogonadal, overweight men with type II diabetes by altering body composition, but studies are conflicting.
Introduction
The prevalence of both hypogonadism and type II diabetes increases with age. However, it is unclear whether hypogonadism contributes to type II diabetes, whether type II diabetes contributes to the development of hypogonadism, or whether the two are linked by an aging-associated condition such as increased fat mass ( Figure 1 ). As with other agingassociated medical conditions, investigators have sought to isolate the effects of age, per se, in these two conditions. Recent studies have focused on the effects of increased adiposity and decreased lean body mass in diabetic and in hypogonadal men. This review will examine current understanding, including recent studies of testosterone (T) replacement, and project some possible mechanisms for the established observations.
Hypogonadism and aging
Both cross-sectional and longitudinal studies indicate that testosterone levels fall with age. As testosterone levels are greatly affected by sex hormone-binding globulin (SHBG) levels, it is useful to appreciate how testosterone circulates. Total testosterone levels are comprised of SHBG-bound testosterone, albumin-bound testosterone, and free testosterone, which accounts for only about 1-3% of total testosterone ( Figure 2 ). Cross-sectional studies demonstrate an age-related fall in total testosterone levels even when the mean body mass index (BMI) does not exceed 26 kg/m 2 . [1] [2] [3] These studies also demonstrate an age-related increase in SHBG levels and a decrease in bioavailable and free testosterone concentrations. While most of the participants in these studies were Europeans or European-Americans, Perry et al 4 also found agerelated reductions in total and bioavailable testosterone levels in African-American men. Longitudinal studies have confirmed these findings. [5] [6] [7] Feldman et al 7 reported that total testosterone levels declined cross-sectionally at 0.8% per year of age, whereas both free and albumin-bound testosterone declined at about 2% per year. SHBG levels increased at 1.6% per year; luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels also tend to rise with age. Tenover et al 8 noted that in aging men treated with the antiestrogen clomiphene citrate, the increase in bioavailable testosterone that is observed in younger men undergoing the same treatment was blunted, even though LH pulse characteristics and bioactive LH levels were similar in the two groups. This study indicates that the major age-related changes in testosterone levels are caused by changes at the testicular level, and that the hypothalamic-pituitary responsiveness is maintained in aging men.
Hypogonadism: a risk factor for diabetes?
Is hypogonadism a risk factor for development of type II diabetes? Haffner et al 9 reported that changes in SHBG in women, but not in men, predicted subsequent development of type II diabetes. However, in 1996, using data from the Multiple Risk Factor Intervention Trial (MRFIT) study, these investigators reported that low levels of SHBG and total testosterone may also be predictive of the development of diabetes in men. 10 The Massachusetts Male Aging Study prospectively evaluated 1709 men living in the Boston area from 1987 to 1989 and again 7-10 y later. 11 They found that for each decrease of 1 standard deviation (s.d.) in free testosterone (4 ng/dl), there was a 1.58-fold increased risk for developing diabetes; and for each decrease of 1 s.d. in SHBG (16 nmol/l), there was a 1.89-fold increased risk for developing diabetes (both Po0.02). While interesting, the lack of baseline glucose and insulin levels and the reliance upon self-reporting of diabetes make these observations questionable at best. More recently, investigators from the Rancho Bernardo Study reported findings in 294 men, aged 55-89 y, who were evaluated with fasting and 2-h glucose and insulin levels following a 75-g glucose tolerance test. 12 They found that total, but not bioavailable, testosterone levels were inversely related to subsequent development (within 8 y) of diabetes. After controlling for baseline age, BMI, and systolic blood pressure, subjects with a low total testosterone had a 2.7-fold higher risk for developing diabetes. A potential limitation in this study is that each subject only had a single measurement of testosterone. Furthermore, it is difficult to generalize the findings of the Massachusetts Male Aging Study and the Rancho Bernardo Study to all races, as the populations studied were more than 95% European American.
Prevalence of hypogonadism in individuals with type II diabetes
Clinicians have known for years that many individuals with type II diabetes have low total testosterone levels (Table 1) , but it was not clear if this finding was due to the association of both conditions with age, or if there was a direct relationship between them. Between 1972 and 1974, BarrettConnor et al, 13 in the Rancho Bernardo Study, evaluated 985 men aged 40-79 y. The 110 men with diabetes had lower total testosterone levels and lower SHBG levels than did the nondiabetic men, even after adjustment for BMI and age: 21% of diabetic men compared with 13% of nondiabetic men had testosterone levels below 350 ng/dl. Fasting glucose levels and total testosterone levels were inversely correlated. In a study of aging men (mean age 73 y) with at least one symptom of testosterone deficiency, Tan and Pu 14 found that 64% of those with diabetes had total testosterone levels below 300 ng/dl, compared with 38% of nondiabetic men. These reports indicate that low total testosterone levels are more common in older diabetic than in nondiabetic men of the same age. However, lower total testosterone levels could be merely a manifestation of reduced SHBG levels. Do diabetic men also 45 z5 million men are thought to be hypogonadal. 46 Figure 2 Composition of total testosterone. 47 SHBG, sex hormone-binding globulin; T, testosterone.
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Bioavailable testosterone and glucose tolerance
Goodman-Gruen and Barrett-Connor 15 evaluated 775 men over 55 y of age with a 75-g oral glucose tolerance test and determined that 15% had type II diabetes. These diabetic men were significantly older than the men with normal glucose tolerance and had somewhat greater waist circumference and waist : hip ratio (WHR), even though their mean BMIs were similar. Both total and bioavailable testosterone were inversely associated with BMI and WHR; however, only total testosterone was significantly and inversely associated with glycemia. This indicates that differences between diabetic and nondiabetic men may be due to changes in SHBG rather than in testosterone production.
Factors affecting SHBG levels
Several common conditions affect circulating SHBG levels ( Table 2 ). Most population-based studies have observed that SHBG levels fall with obesity 16 and increase with aging. 6 Fat mass in men also increases with aging. 17, 18 The linkage of obesity with SHBG may be mediated by insulin resistance in peripheral tissues, resulting in higher insulin levels that suppress hepatic production of SHBG. 19 As previously noted, Barrett-Connor et al 13 observed that diabetic men had reduced SHBG levels even when corrected for BMI. In contrast, Abate et al 20 studied diabetic and nondiabetic men with similar body fat and found that SHBG levels were similar. Estrogen treatment and high estrogen states such as pregnancy increase SHBG levels, while androgen therapy, especially when pharmacologic, suppresses SHBG. Thus, it is likely that the estrogen/androgen ratio is an important regulator of SHBG levels. A high phytoestrogen and high fiber diet will increase SHBG levels. 21 Hyperthyroidism 22 increases and hypothyroidism decreases SHBG levels. Hepatic cirrhosis 23 and some antiepileptic drugs enhance SHBG synthesis. 24 The combined effect of aging and obesity on SHBG levels in diabetic patients is not yet clear. Andersson et al 25 found higher serum plasma insulin levels and lower levels of SHBG in dietcontrolled diabetic men when compared with age and BMI-matched nondiabetic men. However, the mean BMI in the diabetic study population was only 26.8 kg/m 2 , which is considerably less than that observed in obese diabetic populations in the United States.
SHBG and hormonal abnormalities tend to normalize following significant weight loss. Strain et al 26 observed an increase in SHBG with weight loss. Vertical gastroplasty of 19 morbidly obese men caused a significant weight loss, and after 12 months, a significant decrease in estradiol levels and an increase in FSH, total testosterone, and SHBG levels occurred. 27 These observations provide further support for the effects of obesity on SHBG and testosterone.
Regulation of testosterone secretion in obese men SHBG and total testosterone levels are decreased and estrogen levels are increased in men with obesity, but discordant findings have been reported for free testosterone levels (Table 3) . Schneider et al 28 noted that estrone and estradiol levels were increased two-fold in morbidly obese men, but free testosterone concentrations were normal. The metabolic clearance rate of testosterone and the peripheral conversion of testosterone to estradiol and androstenedione to estrone were increased in the obese men. However, the obese men exhibited normal LH and testosterone responses to clomiphene citrate, indicating that the hypothalamic- ) and compared them with nonobese controls. They observed a highly significant negative correlation (Po0.001) between plasma-free testosterone levels and BMI and a positive correlation between estradiol levels and BMI. LH pulsatility was similar in the two groups, but mean diurnal LH pulse amplitude was significantly lower in the obese group. Vermeulen et al concluded that the basic defect was at the hypothalamic-pituitary level. Strain 26 has reported that weight loss increases total testosterone, free testosterone, and SHBG levels. No change was observed in LH, estradiol, or estrone levels. Dexamethasone was found to suppress estradiol, free estradiol, estrone, androstenedione, and SHBG levels, but had no effect on LH, total, and free testosterone in the obese men. 30 These observations suggest that the elevated estrogen levels observed in obese men were dependent upon adrenal hormones. There is also some evidence that endogenous opioids may act to suppress gonadotropin-releasing hormone secretion in obese men. 31 Lima et al 32 divided obese men into those with BMI of 35 kg/m 2 or less and those with a BMI of 35.1 kg/ m 2 or higher and studied them before and after 6 months of a hypocaloric diet (1200 kcal/day) plus dexfenfluramine 15 mg twice a day. Both groups of obese men had significant reductions in total and free testosterone when compared with normal men. Free testosterone and LH levels were significantly lower in the most obese group. After weight loss, fasting insulin levels were reduced, while total testosterone, free testosterone, and LH levels were increased (Po0.01). The investigators concluded that free testosterone levels are dependent on the degree of obesity.
In summary, obesity is associated with increased peripheral conversion of adrenal steroids into estradiol and estrone. With increasing obesity there is an increase in estrogen and insulin levels. This is associated with suppression of the HPT axis and a decrease in free testosterone levels. In contrast, aging is associated with a decrease in total testosterone levels, an increase in SHBG levels, and a decrease in free testosterone and bioavailable testosterone levels. While the described findings in obesity provide a likely scenario in obese diabetic men, we are not aware of good studies in aging diabetic men that have correlated free testosterone levels (using reliable measurements) and changes in the HPT axis with the degree of obesity.
Several investigators have attempted to isolate the effects of insulin and glucose levels on testosterone levels. Pasquali et al 33 reported that insulin suppression with diazoxide for 7 days reduced insulin and testosterone (total and free) levels and increased SHBG and LH levels for both obese and nonobese men. In a subsequent study, this group performed acute hyperinsulinemic-euglycemic clamp studies in normal-weight and obese men. 34 Basal testosterone levels (10.473.02 nmol/l) were lower in obese diabetic patients than in normal-weight controls (15.5074.65 nmol/l, Po0.01). During this clamp study, testosterone was significantly increased in the obese group (11.7973.64 nmol/l, Po0.05) but not in the control group (15.8174.54 nmol/l, P ¼ NS). The authors suggest that insulin may have some effect on testosterone secretion. Oltmanns et al 35 performed euglycemic and hypoglycemic hyperinsulinemic clamp studies on 30 young healthy men. Hypoglycemia resulted in acute suppression of testosterone secretion, but hyperinsulinemia did not affect testosterone levels. This study indicates that, at least in young, healthy, nondiabetic men, the major effects of hyperinsulinemia on testosterone levels are mediated through the suppression of SHBG production, and not by an effect on testosterone production. As hypoglycemia suppresses testosterone production, it seems unlikely that hyperglycemia, per se, would likewise suppress testosterone production. In fact, testosterone levels are elevated in young adult men with type I diabetes. 36 However, this finding may reflect increased SHBG levels and an insulin-deficient state. 37 Together, these data suggest that a reduction in SHBG levels results in low total testosterone levels in type II diabetic patients. SHBG levels are inversely related to obesity and to insulin levels. Free testosterone levels may be normal in men with moderate obesity, but they fall with increasing 
HPT, hypothalamic-pituitary-testicular; SHBG, sex hormone-binding globulin; LH, luteinizing hormone; and T, testosterone.
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Testosterone treatment of testosteronedeficient men
Testosterone replacement therapy (TRT) is associated with changes in body composition. TRT causes an increase in lean body mass in younger men, 38, 39 in middle-aged men, 40, 41 and in aging men. 42 The effect of TRT on adipose tissue has been somewhat less consistent, probably because of differences in body fat. Studies in middle-aged 40 and older men 42 (Tenover, personal communication) have consistently demonstrated a reduction in fat mass in response to TRT.
Androgen treatment of middle-aged men may increase insulin sensitivity. Mårin et al 43 treated 31 obese men, whose mean testosterone level was 4.5 ng/ml, with testosterone or dihydrotestosterone (DHT) gel for 9 months. The testosterone-treated group had a significant reduction in visceral fat mass and an improvement in glucose disposal. DHT did not cause significant changes in these parameters. A small 3-month randomized trial with TRT, DHT, or placebo in androgen-deficient men supports the previous study with regard to TRT. 44 These investigators report that DHT treatment (at higher doses than in the previous study) also improved insulin sensitivity. The effects of androgen treatment on insulin sensitivity may be caused by the change in body composition and by inhibition of lipoprotein lipase activity, resulting in reduced triglyceride uptake and accelerated triglyceride release from abdominal adipose tissue. The reduction in adipose tissue may also decrease circulating free fatty acids, resulting in an improvement in insulin sensitivity.
We are aware of two unpublished studies in which testosterone was administered to obese, type II diabetic men with low serum total testosterone levels. Although changes in insulin sensitivity were not observed, neither study observed significant changes in body composition in response to testosterone. Accordingly, it was not possible to determine whether effective TRT altered insulin sensitivity in type II diabetic men.
Conclusion
Obesity and aging seem to be the common factors in decreased levels of total and free testosterone in type II diabetic patients. The increase in total testosterone levels that accompanies significant weight loss and the improvement in body composition that results from androgen replacement therapy indicate that these changes in testosterone levels in diabetic patients are potentially reversible. While weight reduction should be the first goal, there is potential benefit in normalizing total and free testosterone levels in those men who fail to achieve normal levels by weight reduction. Studies in this patient population would be required to confirm this hypothesis. The potential ability of testosterone replacement through regulated TRT to slow or prevent the development of diabetes in prediabetic men also deserves further examination. While it appears that this therapy may have beneficial effects on cardiovascular risk factors, one must recognize that testosterone replacement in aging men has the potential risks of excessive erythrocytosis and adverse effects on benign prostatic hyperplasia and prostate cancer. Understanding the risk/benefit ratio requires a large clinical trial. Until such a trial is conducted, one must discuss the potential benefits and risks with patients prior to giving TRT. If treatment is provided, periodic monitoring of the hematocrit and of the prostate using digital rectal examinations and prostate-specific antigen tests in men over age 50 y is essential.
Discussion
Dr Lisa Tenover: Do you think that hypogonadism contributes to the high prevalence of erectile dysfunction (ED) in patients with diabetes? Dr Glenn Cunningham: Yes, it probably contributes, and diabetic patients with ED should definitely be screened for low testosterone. However, the majority of ED in diabetic patients is due to vascular and/or neuropathic changes, not to hormonal problems. Dr Ridwan Shabsigh: How about the rare genetic disorders, such as Klinefelter syndrome and PraderWilli syndrome, that are associated with diabetes and hypogonadism? Do these disorders shed any light on the association between testosterone levels and diabetes? Dr Cunningham: Not yet. About one in every 400 to 600 male infants have Klinefelter's syndrome. Prader-Willi syndrome is much rarer. In each syndrome, there are a number of confounding factors. For instance, patients with Prader-Willi syndrome are generally very overweight, so we go back to the connection between obesity and diabetes and obesity and hypogonadism. In addition, Klinefelter's syndrome may have an autoimmune component, and this makes it hard to determine whether the changes seen are due to autoimmune reactions or to other pathophysiologic events.
Dr Adrian Dobs: Does it matter which testosterone formulation is used for testosterone replacement therapy in men with diabetes? Dr Cunningham: Some testosterone preparations, such as the topical formulations, are more userfriendly than others. However, transdermal formulations are very expensive, which is a problem for many patients, particularly patients whose managed care plans will not pay for them and for older patients on Medicare. Pharmacokinetics also differ among the various testosterone formulations. Intramuscular injections can provide flexibility in dosing. More favorable blood levels of testosterone can be achieved by administering lower doses more frequently. About half of the patients in my practice who use injectable formulations can self-administer the treatment.
